LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer.
Nature communications
Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, Cai Z, Zhu M, Li Q, Li Y, Wang J, Liu Y, Wu Z, Song E, Liu Q.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2020
Cancer Research
No items found.
Key Finding
Moreover, it reveals the novel mechanism of DILA1 in regulating Cyclin D1 protein stability and suggests DILA1 is a specific therapeutic target to downregulate Cyclin D1 protein and reverse tamoxifen resistance in treating breast cancer.
Countstar Connection
A Countstar instrument quantified breast cancer cell numbers during growth assessment in the tamoxifen-resistance experiments.
